ATE318896T1 - Rekombinante rna-replikase von hepatitis-c-virus - Google Patents

Rekombinante rna-replikase von hepatitis-c-virus

Info

Publication number
ATE318896T1
ATE318896T1 AT96933178T AT96933178T ATE318896T1 AT E318896 T1 ATE318896 T1 AT E318896T1 AT 96933178 T AT96933178 T AT 96933178T AT 96933178 T AT96933178 T AT 96933178T AT E318896 T1 ATE318896 T1 AT E318896T1
Authority
AT
Austria
Prior art keywords
hcv
rdrp
hepatitis
virus
vitro
Prior art date
Application number
AT96933178T
Other languages
English (en)
Inventor
Curt H Hagedorn
Reinoldus H Al
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE318896T1 publication Critical patent/ATE318896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96933178T 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus ATE318896T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US438395P 1995-09-27 1995-09-27

Publications (1)

Publication Number Publication Date
ATE318896T1 true ATE318896T1 (de) 2006-03-15

Family

ID=21710540

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933178T ATE318896T1 (de) 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus

Country Status (8)

Country Link
US (2) US5981247A (de)
EP (1) EP0859833B1 (de)
JP (1) JP4191797B2 (de)
AT (1) ATE318896T1 (de)
AU (1) AU719122B2 (de)
CA (1) CA2233309A1 (de)
DE (1) DE69635864T2 (de)
WO (1) WO1997012033A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
FR2761695B1 (fr) * 1997-04-04 1999-09-24 Bio Merieux Arn polymerase fonctionnant preferentiellement sur matrice d'arn, sa preparation et son utilisation
EP1037974B1 (de) * 1997-12-11 2007-10-03 SmithKline Beecham Corporation Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren
AU2787199A (en) 1998-02-25 1999-09-15 Emory University 2'-fluoronucleosides
AU768177B2 (en) * 1998-04-02 2003-12-04 Viropharma Incorporated Hepatitis C virus NS5B compositions and methods of use thereof
EP1090997A4 (de) 1998-06-24 2002-07-03 Int Reagents Corp Von hcv abgeleitetes rna-polymerasegen
AU2181800A (en) * 1998-12-10 2000-06-26 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
EP1600452A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
EP1270737A4 (de) * 2000-04-07 2004-06-16 Shionogi & Co Testverfahren mit vorinkubationsschritt
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
GB0029539D0 (en) * 2000-12-04 2001-01-17 Isis Innovation Method for identifying modulatorss of transcription
IL156457A0 (en) * 2001-01-31 2004-01-04 Bristol Myers Squibb Pharma Co An in-vitro method for genomic replication
WO2002095002A2 (en) * 2001-05-22 2002-11-28 University Of Chicago N4 virion single-stranded dna dependent rna polymerase
US20030170810A1 (en) * 2001-09-18 2003-09-11 Masoud Vedadi Methods and apparatuses for purification
WO2003027330A1 (en) * 2001-09-25 2003-04-03 Xencor Rna dependent rna polymerase mediated protein evolution
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Ｈｃｖ 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
WO2003044168A2 (en) * 2001-11-16 2003-05-30 University Of Massachusetts Facilitation of rna interference
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
CN1852915A (zh) 2003-07-25 2006-10-25 艾登尼科斯（开曼）有限公司 治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物
WO2005070957A1 (en) * 2004-01-09 2005-08-04 Merck & Co., Inc. Hcv rna-dependent rna polymerase
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
CA2597683A1 (en) 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside prodrugs for treating viral infections
AR056327A1 (es) 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2010014134A1 (en) 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2166016A1 (de) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidat-Derivate von Nukleosiden
EP2376515A1 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthese von purinnukleosiden
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011023801A1 (en) 2009-08-31 2011-03-03 F. Hoffmann-La Roche Ag Hcv ns3/4a replicon shuttle vectors
AU2010317996A1 (en) 2009-11-14 2012-05-10 F. Hoffmann-La Roche Ag Biomarkers for predicting rapid response to HCV treatment
CA2772285A1 (en) 2009-12-02 2011-06-09 F. Hoffmann-La Roche Ag Biomarkers for predicting sustained response to hcv treatment
US20110245328A1 (en) 2010-03-31 2011-10-06 Hyunsoon Kang HCV NS5A Replicon Shuttle Vectors
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
US8680071B2 (en) 2010-04-01 2014-03-25 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2012010663A1 (en) 2010-07-22 2012-01-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
EP2691409B1 (de) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
JP2014526474A (ja) 2011-09-12 2014-10-06 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
EP2768838A1 (de) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituierte 3 ', 5 '-cyclophosphate von purin-nukleotid-verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal

Also Published As

Publication number Publication date
JPH11514862A (ja) 1999-12-21
CA2233309A1 (en) 1997-04-03
AU719122B2 (en) 2000-05-04
WO1997012033A1 (en) 1997-04-03
EP0859833A4 (de) 2001-03-28
EP0859833A1 (de) 1998-08-26
US6248589B1 (en) 2001-06-19
DE69635864T2 (de) 2006-10-26
JP4191797B2 (ja) 2008-12-03
AU7200796A (en) 1997-04-17
EP0859833B1 (de) 2006-03-01
DE69635864D1 (de) 2006-04-27
US5981247A (en) 1999-11-09

Similar Documents

Publication Publication Date Title
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
Borman et al. elF4G and its proteolytic cleavage products: effect on initiation of protein synthesis from capped, uncapped, and IRES-containing mRNAs.
Kessler et al. Bone morphogenetic protein-1: the type I procollagen C-proteinase
Wirth et al. How a single Sindbis virus mRNA directs the synthesis of one soluble protein and two integral membrane glycoproteins
Denkewalter et al. Total synthesis of an enzyme. I. Objective and strategy
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
UA48936C2 (uk) Спосіб одержання вірусу курячої анемії (cav) у дволанцюговій формі, рекомбінантна нуклеїнова кислота (варіанти), діагностичний набір (варіанти), вакцинний препарат (варіанти), культура клітин (варіанти), спосіб одержання діагностичного набору (варіанти)
Barth et al. The oligomerization reaction of the Semliki Forest virus membrane protein subunits.
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
GB9722320D0 (en) Human cell cycle checkpoint proteins
WO1990003435A3 (fr) Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle
GB9810999D0 (en) Materials and methods relating to the expression of genes
Hansen et al. Presence of the cap-binding protein in initiation factor preparations from poliovirus-infected HeLa cells
Tanese et al. Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase
Robert et al. Interactions with tRNALys induce important structural changes in human immunodeficiency virus reverse transcriptase
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
AP2368A (en) Novel expression vectors and uses thereof.
Skoging-Nyberg et al. MXI motif of Semliki Forest virus capsid protein affects nucleocapsid assembly
GR3007909T3 (de)
EP0282330A3 (de) Verfahren zur Stimulierung der Genexpression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties